Fig. 2: Antitumor activity of lenvatinib and modulation of NRP1 expression in the in vitro models of HCC. | Acta Pharmacologica Sinica

Fig. 2: Antitumor activity of lenvatinib and modulation of NRP1 expression in the in vitro models of HCC.

From: Hepatocellular carcinoma cells loss lenvatinib efficacy in vitro through autophagy and hypoxia response-derived neuropilin-1 degradation

Fig. 2

Different concentrations of lenvatinib ranging from 0.5 to 30 µM were used for the treatment of HCC cells during 48 h to determine the effects on (a) cell viability by CellTiter-Glo® assay, (b) colony formation assay, and (c) nuclear translocation of Ki67 by ICC and confocal microscopy. NRP1 expression was analyzed at (d) mRNA levels by qRT-PCR, and at protein levels by (e) Western blot and (f) ICC after 48 h of 2.5 and 5 µM lenvatinib treatment. Data from (a) are represented as % of cell viability relative to non-treated cells ± SD (n = 7). Data from (b–f) are represented as mean values of arbitrary units (a.u.) ± SD (n = 3). Bar graphs from (c) and (f) represent the nuclear CTCF ratio of Ki67 and NRP1 CTCF ratio, respectively. Magnification 63×, scale bar 10 µm. e A representative immunoblot is shown. *P < 0.05, **P < 0.01, ***P < 0.001 and ns, not significant vs non-treated cells.

Back to article page